Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

Center for Research on Complex Generics (U18) Clinical Trials Optional

Active
Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The Food and Drug Administration is seeking to establish a Center for Research on Complex Generics through a cooperative agreement to improve patient access to safe and effective generic drugs. This initiative aims to bridge the gap between the FDA and the generic drug industry by identifying scientific challenges in product development and creating a collaborative forum for experts from academia and industry to conduct research. The center will focus on coordinating research projects specifically related to complex generics, hosting scientific workshops, and providing educational training. A key requirement of the program is to ensure free and open public access to research outcomes, including scientific articles and presentations. This effort is designed to complement existing regulatory science programs by serving as a central hub for engagement between the FDA and various public and private stakeholders.

General Info

FDA establishes center to advance research, collaboration, and open science for complex generic drugs.

Agency

Department Of Health And Human Services → Food And Drug Administration

Place of Performance

Not specified

Set-Aside

NONE

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

Posted

forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → Food And Drug Administration
Contacts1 person available
OfficeUSA
Organization / Agency
Department Of Health And Human Services → Food And Drug Administration
Office AddressUSA
Contacts

Full Description

Show more

The Food and Drug Administration (FDA) seeks to fund a Center for Research on Complex Generics under the terms and conditions of a cooperative agreement. The Center for Research on Complex Generics will support the FDA's efforts to enhance collaborations with the generic drug industry relating to generic drug research, to further the FDA's mission of increasing patient access to high quality, safe, and effective generic drugs.


The goals of a Center for Research on Complex Generics include: 


1) Facilitating engagement with generic industry representatives to help identify scientific challenges for generic product development or assessment, and helping to inform FDA about priority areas for research to address these challenges by supporting engagement and coordination between the FDA and key generic industry industry associations, companies, and representatives.


2) Providing a forum for experts from FDA, academia, the generic drug industry, and elsewhere to collaborate on research related to generic products.


3) Coordinating and conducting research projects pertaining to generic products, particularly complex generics.


4) Hosting scientific workshops, providing training, and supporting other educational activities pertaining to generic drug research.


5) Providing free and open public access to generic drug research outcomes such as scientific articles, posters, presentations, and other resources that help the generic drug industry to leverage scientific insights from FDA funded generic drug research.


The Center for Research on Complex Generics is expected to complement FDA's existing regulatory science programs through its specific focus as a hub for coordination and engagement between FDA and the public, including academic experts, generic industry representatives, and other stakeholders.

Similar Contracts

Same NAICS industry code

NAICS: 541715
New
Federal
ACC-DTA Commercial Solutions Opening (CSO)
Solicitation # W912CH-26-S-0001
The Army Contracting Command – Detroit Arsenal (ACC-DTA) Commercial Solutions Opening (CSO), solicitation W912CH-26-S-0001, serves as a rapid-acquisition gateway to transition cutting-edge commercial technologies into active defense programs. This vehicle supports a diverse customer base, including the Intelligence and Security Command (INSCOM) and six Portfolio Acquisition Executives, focusing on the development, integration, and sustainment of ground vehicle systems to enhance Army modernization and readiness. The CSO utilizes a streamlined, merit-based, multi-phased evaluation process consisting of solution briefs, presentations, and commercial solution proposals. Awards may be issued through 2028 as FAR Part 12 contracts or non-FAR agreements, such as Other Transaction Authority (OTA) and Cooperative Agreements. The solicitation is organized around various Areas of Interest (AoI) that address critical military needs. Key initiatives include the FALCONS prototype effort for long-range reconnaissance sensors with funding ceilings between 24 million and 30 million dollars, the TIGER Readiness and Hackathon programs for Abrams Main Battle Tank engine supply chain resilience, and requirements for Counter-Unmanned Aircraft Systems (C-UAS) detection, Mobile Camouflage Systems, and Light Tactical Trailer Heavy Chassis. Technical evaluations focus on mission viability and prototype execution, while price proposals are assessed for affordability. To be eligible for award, companies must be registered in the System for Award Management (SAM) with a Unique Entity ID and comply with the Buy American Act and Specialty Metals clauses.
W6QK Acc- Dta

POSTED

about 12 hours ago

DEADLINE

in about 2 years
View Details
NAICS: 541715
New
Federal
BAA DEVCOM AC Emerging Technologies
Solicitation # W15QKN-26-S-1AZR
The U.S. Army Combat Capabilities Development Command Armaments Center is soliciting research proposals and white papers for new and innovative technologies related to emerging weapons, munitions systems, and soldier lethality. Issued under FAR 6.102(d)(2), this Broad Agency Announcement is a continuously open solicitation effective from March 5, 2026, through March 4, 2031. The program seeks to advance the state of the art through collaborations with industry and academia, with a particular interest in scientific study and experimentation that fills technology needs across the product life cycle, including improvements in armament packaging, ammunition logistics, and micro-system architecture. The submission process is a two-stage effort beginning with a white paper, which is limited to six pages plus a cover page and biographical sketches. Offerors whose white papers are favorably evaluated may be invited to submit a full research proposal. The government prefers proposals covering a three-year period of performance with incremental funding. Awards are based on a competitive selection process evaluating overall scientific and technical merit, potential contributions to the Army mission, offeror capabilities, personnel qualifications, past performance, and proposed price. All submissions must be unclassified and adhere to strict formatting guidelines, including 12-point Times New Roman font for narrative text.
W6QK Acc-Ri-Picatinny

POSTED

about 12 hours ago

DEADLINE

in over 4 years
View Details
NAICS: 541715
New
Federal
Common Autonomous Multi-Domain Launcher (CAML)-Lite Prototype Effort
Solicitation # W50RAJ27CAML_LITE
The Common Autonomous Multi-Domain Launcher (CAML)-Lite Prototype Effort is a competitive procurement conducted under 10 U.S.C. section 4022 for the development of a mobile, optionally manned, autonomous launcher designed to increase survivability and reduce manned support for cross-domain fires. Managed by the Department of Defense, this effort utilizes Other Transaction Agreements (OTAs) and follows a two-phase structure. Phase 1 focuses on a government-sponsored prototype demonstration at Talisman Sabre 2027 in August 2027, with options for the government to acquire additional prototype units, new equipment training, and contractor logistics support. Phase 2 involves maturing selected solutions into a production-representative configuration integrated into a common CAML architecture. The procurement process begins with a Request for Solutions Brief to identify meritorious respondents, who will then be invited to submit a Request for Prototype Proposal. Key technical requirements include the use of a Modular Open Systems Approach (MOSA) to ensure interchangeable modules and common interfaces. Performers are required to assume full responsibility for international logistics and compliance for the Phase 1 demonstration and must adhere to minimum Right to Repair requirements as a condition of award. Selection for Phase 1 is based on the feasibility of the maturation path and the technical soundness of the approach, while subsequent option exercises will prioritize speed of delivery, technical performance, property rights, and the right to repair. Phase 1 OTA awards are expected by December 18, 2026, with a firm-fixed-price payment structure split between award and demonstration completion.
W6DV Peo M & S Redstone

POSTED

1 day ago

DEADLINE

in about 21 hours
View Details
NAICS: 541715
New
Federal
Fast Assessment of Solutions, Therapeutics, Pharmaceuticals, and SupplieS (FASTPASS) Innovative Solutions Opening
Solicitation # ARPA-H-SOL-26-160
The Fast Assessment of Solutions, Therapeutics, Pharmaceuticals, and Supplies (FASTPASS) program, under solicitation ARPA-H-SOL-26-160, is an initiative by the Advanced Research Projects Agency for Health (ARPA-H) to develop a near real-time, non-destructive, AI-enabled screening system. The goal is to identify contamination, adulteration, and quality defects in pharmaceutical products through their packaging at ports of entry and other supply-chain nodes using multi-modal sensing and data fusion. This 54-month program is structured into three 18-month phases, culminating in a fieldable platform with validated training materials and integrated documentation capabilities. This procurement is conducted as a multiple-award Other Transaction (OT) Agreement rather than a standard federal contract, meaning it is governed by specific OT articles instead of the Federal Acquisition Regulation. Awards are based on the most advantageous proposals, with primary evaluation factors including innovation, soundness, execution planning, risk management, and team expertise. Payments are fixed and triggered by the successful completion of milestones, managed through the Payment Management System. Proposers must be registered in SAM.gov and provide detailed technical and cost proposals, including a milestone payment schedule and research security disclosures. Amendment 01 specifically updated the cost proposal narrative model and workbook to correct typographical errors and rename appendices.
Advanced Research Projects Agency For Health (arpa-H)

POSTED

1 day ago

DEADLINE

in 19 days
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS